SWOG clinical trial number
SWOG-9449 (INT-0156) (E1C93)

Phase II Study of VIP (Etoposide, Ifosfamide and Cisplatin) in the Treatment of Invasive Thymoma

Closed
Phase
Published
Abbreviated Title
Phase II Study of VIP (Etoposide, Ifosfamide and Cisplatin) in the Treatment of Invasive Thymoma
Activated
09/01/1995
Closed
02/27/1997

Research committees

Lung Cancer

Publication Information Expand/Collapse

2001

Combined etoposide, ifosfamide, and cisplatin in the treatment of patients with advanced thymoma and thymic carcinoma: an Intergroup trial

PJ Loehrer;M Jiroutek;S Aisner;J Aisner;M Green;CR Thomas;R Livingston;DH Johnson Cancer 91(11):2010-2015

1998

Phase II trial of etoposide (V), ifosfamide (I) plus cisplatin (P) in patients with advanced thymoma (T) or thymic carcinoma (TC): Preliminary results from an ECOG coordinated intergroup trial.

PJ Loehrer;M Jiroutek;S Aisner;J Aisner;MR Greene;CR Thomas Jr;RB Livingston;DH Johnson Proc of the American Society of Clinical Oncology 17:30a(#118)

Other Clinical Trials

SWOG Clinical Trial Number
S2302

PRAGMATICA - LUNG: A PROSPECTIVE RANDOMIZED STUDY OF RAMUCIRUMAB (LY3009806; NSC 749128) PLUS PEMBROLIZUMAB (MK-3475; NSC 776864) VERSUS STANDARD OF CARE FOR PARTICIPANTS PREVIOUSLY TREATED WITH IMMUNOTHERAPY FOR STAGE IV OR RECURRENT NON-SMALL CELL LUNG CANCER
Research Committee(s)
Lung Cancer
Activated
03/06/2023
Accrual
85%
Open
Phase
SWOG Clinical Trial Number
A082002

A Randomized Phase II/III Trial of Modern Immunotherapy Based Systemic Therapy with or Without SBRT for PD-L1-Negative, Advanced Non-Small Cell Lung Cancer
Research Committee(s)
Lung Cancer
Activated
12/21/2021
Open
Phase
SWOG Clinical Trial Number
CTSU/NRG-LU007

RAndomized Phase II/III Trial Of Consolidation Radiation + Immunotherapy for ES-SCLC: RAPTOR Trial
Research Committee(s)
Lung Cancer
Activated
08/17/2020
Open